Differences in Cancer Rates Seen Among Asian American and Native Hawaiian/Pacific Islander PopulationsJanuary 29, 2016
Significant differences in cancer rates were found between Asian Americans and Native Hawaiians/Pacific Islanders (AANHPIs), according to a special report within Cancer Facts & Figures 2016.
South Asian women are more likely to have later stage breast cancer at diagnosis compared with the general population, research has shown.
When patients with cancer in different Asian American subgroups were examined, their cancer-specific mortality was found to be far lower than that of non-Hispanic white patients.
One tenth of younger leukemia patients of East Asian ancestry inherit a gene variation associated with lowered tolerance of an indispensable drug for acute lymphoblastic leukemia (ALL).
Writing down fears, emotions, and the benefits of a cancer diagnosis may improve health outcomes for Asian American survivors of breast cancer, according to a new study. The research investigated methods of reducing the psychological burden among minority patients, particularly among breast cancer survivors.
Researchers identified a rare type of melanoma that disproportionately attacks the plams and soles and under the nails of people who have darker skin, is not caused by sun exposure, and is almost twice as likely to recur than other other similar types of skin cancer.
A recent study has found that, within the Asian population, the frequency of epidermal growth factor receptor mutations associated with other demographic and clinical characteristics is higher than previously reported, even in patients with a history of smoking.
Race/ethnicity varied the associations between an extreme body mass index or high waist-to-hip ratio and increased risk for mortality among patients with breast cancer.
Disparities in survival after breast cancer persist across racial and ethnic groups even after adjusting for demographics such as patients' education and the socioeconomic status of the neighborhood where they lived.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|